Note 13 - Segment Information: SEGMENT Income Loss Table (Details) - USD ($)	12 Months Ended
	Apr. 30, 2017	Apr. 30, 2016
Details
Net revenues - Chinese Medicines	$ 2,879,795	$ 2,405,944
Net revenues - Chinese medicine - related party	0	0
Net revenues - Chinese medicine - Total	2,879,795	2,405,944
Net revenues - Stevioside - third party	10,619,522	6,910,791
Net revenues - Stevioside - related party	5,855,594	8,698,333
Net revenues - Stevioside - Total	16,475,116	15,609,124
Net revenues - Total segment and consolidated revenues	19,354,911	18,015,068
Interest income - Chinese Medicines	0	0
Interest income - Stevioside	(395,654)	(283,028)
Interest income - Total segment and consolidated interest expense	(395,654)	(283,028)
Depreciation and amortization - Chinese Medicines	288,868	373,370
Depreciation and amortization - Stevioside	1,438,124	1,002,072
Depreciation and amortization - Total segment and consolidated depreciation and amortization	1,726,992	1,375,442
Loss before taxes and noncontrolling interest - Chinese Medicines	759,574	432,377
Loss before taxes and noncontrolling interest - Stevioside	1,636,816	3,338,883
Loss before taxes and noncontrolling interest - Corporate and other	1,501,634	1,020,343
Income (loss) before income taxes - Total segment and consolidated depreciation and amortization	$ 3,898,024	$ 4,791,603